Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Combined Modality Therapy"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 41-60 z 37344
Tytuł:
Discontinuation risk from adverse events: immunotherapy alone vs. combined with chemotherapy: a systematic review and network meta-analysis.
Autorzy:
Shin S; Lunit, 4th to 8th floors, 374, Gangnam-daero, Gangnam-gu, Seoul, Republic of Korea.
Moon J; Lunit, 4th to 8th floors, 374, Gangnam-daero, Gangnam-gu, Seoul, Republic of Korea.
Oum C; Lunit, 4th to 8th floors, 374, Gangnam-daero, Gangnam-gu, Seoul, Republic of Korea.
Kim S; Lunit, 4th to 8th floors, 374, Gangnam-daero, Gangnam-gu, Seoul, Republic of Korea.
Cho SI; Lunit, 4th to 8th floors, 374, Gangnam-daero, Gangnam-gu, Seoul, Republic of Korea.
Lim Y; Lunit, 4th to 8th floors, 374, Gangnam-daero, Gangnam-gu, Seoul, Republic of Korea.
Ock CY; Lunit, 4th to 8th floors, 374, Gangnam-daero, Gangnam-gu, Seoul, Republic of Korea.
Shin S; Lunit, 4th to 8th floors, 374, Gangnam-daero, Gangnam-gu, Seoul, Republic of Korea. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Jan 30; Vol. 24 (1), pp. 152. Date of Electronic Publication: 2024 Jan 30.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*
Lung Neoplasms*
Humans ; Network Meta-Analysis ; Combined Modality Therapy ; Immunotherapy/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
An update on diagnosis and treatment of hepatoblastoma.
Autorzy:
Cao Y; Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital, Beijing, China.; The First Medical Center of the Chinese PLA General Hospital, Beijing, China.
Wu S; The First Medical Center of the Chinese PLA General Hospital, Beijing, China.
Tang H; Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital, Beijing, China.; The First Medical Center of the Chinese PLA General Hospital, Beijing, China.
Pokaż więcej
Źródło:
Bioscience trends [Biosci Trends] 2024 Jan 30; Vol. 17 (6), pp. 445-457. Date of Electronic Publication: 2023 Dec 23.
Typ publikacji:
Journal Article
MeSH Terms:
Hepatoblastoma*/therapy
Hepatoblastoma*/drug therapy
Liver Neoplasms*/therapy
Liver Neoplasms*/drug therapy
Child ; Humans ; Infant ; Neoplasm Recurrence, Local/surgery ; Combined Modality Therapy ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Hepatectomy/methods ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Heterogeneity in response to treatment across tinnitus phenotypes.
Autorzy:
Niemann U; University Library, Otto von Guericke University Magdeburg, Universitätsplatz 2, Magdeburg, 39106, Germany. .; Faculty of Computer Science, Otto von Guericke University Magdeburg, Universitätsplatz 2, Magdeburg, 39106, Germany. .
Boecking B; Charité-Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, Berlin, 10117, Germany.
Brueggemann P; Charité-Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, Berlin, 10117, Germany.
Spiliopoulou M; Faculty of Computer Science, Otto von Guericke University Magdeburg, Universitätsplatz 2, Magdeburg, 39106, Germany.
Mazurek B; Charité-Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, Berlin, 10117, Germany.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Jan 24; Vol. 14 (1), pp. 2111. Date of Electronic Publication: 2024 Jan 24.
Typ publikacji:
Journal Article
MeSH Terms:
Quality of Life*
Tinnitus*/therapy
Humans ; Combined Modality Therapy ; Precision Medicine ; Phenotype
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
ALA-RDT in GBM: protocol of the phase I/II dose escalation trial of radiodynamic therapy with 5-Aminolevulinic acid in patients with recurrent glioblastoma.
Autorzy:
Pepper NB; Department of Radiation Oncology, University Hospital of Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany. .
Eich HT; Department of Radiation Oncology, University Hospital of Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany.
Müther M; Department of Neurosurgery, University Hospital of Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany.
Oertel M; Department of Radiation Oncology, University Hospital of Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany.
Rehn S; Department of Radiation Oncology, University Hospital of Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany.
Spille DC; Department of Neurosurgery, University Hospital of Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany.
Stummer W; Department of Neurosurgery, University Hospital of Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany.
Pokaż więcej
Źródło:
Radiation oncology (London, England) [Radiat Oncol] 2024 Jan 22; Vol. 19 (1), pp. 11. Date of Electronic Publication: 2024 Jan 22.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Aminolevulinic Acid*
Glioblastoma*/radiotherapy
Humans ; Adolescent ; Adult ; Prospective Studies ; Neoplasm Recurrence, Local/therapy ; Combined Modality Therapy ; Clinical Trials, Phase I as Topic ; Clinical Trials, Phase II as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Chemoembolization versus Radiotherapy for Single Hepatocellular Carcinomas of ≤3 cm Unsuitable for Image-Guided Tumor Ablation.
Autorzy:
Lim J; Department of Gastroenterology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.; Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kim E; Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kim S; Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kim SY; Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kim JH; Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Yoon SM; Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Shim JH; Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Pokaż więcej
Źródło:
Gut and liver [Gut Liver] 2024 Jan 15; Vol. 18 (1), pp. 125-134. Date of Electronic Publication: 2023 Aug 22.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/diagnostic imaging
Carcinoma, Hepatocellular*/therapy
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/diagnostic imaging
Liver Neoplasms*/therapy
Liver Neoplasms*/pathology
Chemoembolization, Therapeutic*/methods
Catheter Ablation*/methods
Humans ; Treatment Outcome ; Retrospective Studies ; Combined Modality Therapy
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Forefronts and hotspots evolution of the nanomaterial application in anti-tumor immunotherapy: a scientometric analysis.
Autorzy:
Cao W; Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China.
Jin M; Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China.
Zhou W; Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China.
Yang K; Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China.; Department of General Surgery, Anhui Public Health Clinical Center, Hefei, 230011, People's Republic of China.
Cheng Y; Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China.
Chen J; Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China.
Cao G; Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China. .
Xiong M; Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China. .
Chen B; Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China. .; Department of Surgery, The People's Hospital of Hanshan County, Ma'anshan, 238101, People's Republic of China. .
Pokaż więcej
Źródło:
Journal of nanobiotechnology [J Nanobiotechnology] 2024 Jan 13; Vol. 22 (1), pp. 30. Date of Electronic Publication: 2024 Jan 13.
Typ publikacji:
Journal Article
MeSH Terms:
Biocompatible Materials*
Nanostructures*
Combined Modality Therapy ; Drug Delivery Systems ; Immunotherapy
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Implementing the time-to-event continual reassessment method in the presence of partial orders in a phase I head and neck cancer trial.
Autorzy:
Patel A; Cancer Research Clinical Trials Unit, University of Birmingham, Birmingham, UK. .
Brock K; Cancer Research Clinical Trials Unit, University of Birmingham, Birmingham, UK.
Slade D; Cancer Research Clinical Trials Unit, University of Birmingham, Birmingham, UK.; Oncology R&D, AstraZeneca, Cambridge, UK.
Gaunt C; Cancer Research Clinical Trials Unit, University of Birmingham, Birmingham, UK.
Kong A; Department of Oncology, King's College London, London, UK.
Mehanna H; Cancer Research Clinical Trials Unit, University of Birmingham, Birmingham, UK.; Institute of Head and Neck Studies and Education, University of Birmingham, Birmingham, UK.
Billingham L; Cancer Research Clinical Trials Unit, University of Birmingham, Birmingham, UK.
Gaunt P; Cancer Research Clinical Trials Unit, University of Birmingham, Birmingham, UK.
Pokaż więcej
Źródło:
BMC medical research methodology [BMC Med Res Methodol] 2024 Jan 13; Vol. 24 (1), pp. 11. Date of Electronic Publication: 2024 Jan 13.
Typ publikacji:
Journal Article
MeSH Terms:
Research Design*
Head and Neck Neoplasms*/drug therapy
Humans ; Combined Modality Therapy ; Maximum Tolerated Dose ; Dose-Response Relationship, Drug ; Computer Simulation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold.
Autorzy:
Schmäche T; Department of Visceral, Thoracic and Vascular Surgery, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, Dresden, 01307, Germany.; National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany.
Fohgrub J; Department of Visceral, Thoracic and Vascular Surgery, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, Dresden, 01307, Germany.; National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany.
Klimova A; National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany.; Institute for Medical Informatics and Biometry, Faculty of Medicine, Technische Universität Dresden, Dresden, Germany.
Laaber K; German Cancer Research Center (DKFZ) Heidelberg, Translational Functional Cancer Genomics, Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
Drukewitz S; National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany.; Core Unit for Molecular Tumor Diagnostics (CMTD), Technical University Dresden, Dresden, Germany.; Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany.
Merboth F; Department of Visceral, Thoracic and Vascular Surgery, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, Dresden, 01307, Germany.
Hennig A; Department of Visceral, Thoracic and Vascular Surgery, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, Dresden, 01307, Germany.; National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany.
Seidlitz T; Department of Visceral, Thoracic and Vascular Surgery, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, Dresden, 01307, Germany.
Herbst F; German Cancer Research Center (DKFZ) Heidelberg, Translational Functional Cancer Genomics, Heidelberg, Germany.; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Baenke F; Department of Visceral, Thoracic and Vascular Surgery, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, Dresden, 01307, Germany.
Ada AM; Department of Visceral, Thoracic and Vascular Surgery, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, Dresden, 01307, Germany.
Groß T; National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany.; Core Unit for Molecular Tumor Diagnostics (CMTD), Technical University Dresden, Dresden, Germany.; German Cancer Consortium (DKTK), Dresden, Germany.
Wenzel C; Institute of Pathology, University Hospital Carl Gustav CarusTechnische Universität Dresden, Dresden, Germany.
Ball CR; National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany.; Department for Translational Medical Oncology, National Center for Tumor Diseases Dresden (NCT/UCC), Dresden, Germany.; Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav CarusTechnische Universität Dresden, Dresden, Germany.; German Cancer Consortium (DKTK), partner side Dresden, Dresden, Germany.; TUD Dresden University of Technology, Faculty of Biology, Technische Universität Dresden, Dresden, Germany.
Praetorius C; Department of Visceral, Thoracic and Vascular Surgery, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, Dresden, 01307, Germany.; National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany.
Schmidt T; Department of General, Visceral and Transplantation Surgery, University Hospital of Heidelberg, Heidelberg, Germany.; Department of General, Visceral, Cancer and Transplantation Surgery, University Hospital of Cologne, Cologne, Germany.
Ringelband-Schilling B; Department of Visceral, Thoracic and Vascular Surgery, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, Dresden, 01307, Germany.
Koschny R; Department of Gastroenterology and Hepatology, University Hospital of Heidelberg, Heidelberg, Germany.
Stenzinger A; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Roeder I; National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany.; Institute for Medical Informatics and Biometry, Faculty of Medicine, Technische Universität Dresden, Dresden, Germany.
Jaeger D; Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.; Clinical Cooperation Unit Applied Tumor-Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Zeissig S; Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany.; Center for Regenerative Therapies (CRTD), Technische Universität Dresden, Dresden, Germany.
Welsch T; Department of Visceral, Thoracic and Vascular Surgery, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, Dresden, 01307, Germany.; Department of General, Visceral, and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Aust D; Institute of Pathology, University Hospital Carl Gustav CarusTechnische Universität Dresden, Dresden, Germany.; Tumour- and Normal Tissue Bank of the University Cancer Center (UCC), University Hospital Carl Gustav Carus, Medical Faculty, Technische Universität Dresden, Dresden, Germany.
Glimm H; National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany.; German Cancer Research Center (DKFZ) Heidelberg, Translational Functional Cancer Genomics, Heidelberg, Germany.; Department for Translational Medical Oncology, National Center for Tumor Diseases Dresden (NCT/UCC), Dresden, Germany.; Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav CarusTechnische Universität Dresden, Dresden, Germany.; German Cancer Consortium (DKTK), partner side Dresden, Dresden, Germany.
Folprecht G; National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany.; Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany.
Weitz J; Department of Visceral, Thoracic and Vascular Surgery, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, Dresden, 01307, Germany.; National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany.
Haag GM; Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.; Clinical Cooperation Unit Applied Tumor-Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Stange DE; Department of Visceral, Thoracic and Vascular Surgery, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, Dresden, 01307, Germany. .; National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany. .
Pokaż więcej
Źródło:
Molecular cancer [Mol Cancer] 2024 Jan 10; Vol. 23 (1), pp. 10. Date of Electronic Publication: 2024 Jan 10.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Stomach Neoplasms*/drug therapy
Adenocarcinoma*/drug therapy
Carbamates*
Pyrazines*
Pyridines*
Humans ; Combined Modality Therapy ; Neoadjuvant Therapy ; Organoids ; Fluorouracil/pharmacology
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Evolution of cell therapy for renal cell carcinoma.
Autorzy:
Wang Y; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Harvard Medical School, Boston, MA, 02215, USA.
Suarez ER; Center for Natural and Human Sciences, Federal University of ABC, Santo Andre, SP, 09210-580, Brazil.; Graduate Program in Medicine - Hematology and Oncology, Federal University of Sao Paulo, São Paulo, SP, 04023-062, Brazil.
Kastrunes G; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
de Campos NSP; Center for Natural and Human Sciences, Federal University of ABC, Santo Andre, SP, 09210-580, Brazil.; Graduate Program in Medicine - Hematology and Oncology, Federal University of Sao Paulo, São Paulo, SP, 04023-062, Brazil.
Abbas R; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Pivetta RS; Center for Natural and Human Sciences, Federal University of ABC, Santo Andre, SP, 09210-580, Brazil.; Graduate Program in Medicine - Hematology and Oncology, Federal University of Sao Paulo, São Paulo, SP, 04023-062, Brazil.
Murugan N; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Chalbatani GM; Department of Immunology, Mayo Clinic, Scottsdale, AZ, 85259, USA.
D'Andrea V; Department of Surgery, Brigham and Women's Hospital, Boston, MA, 02215, USA.
Marasco WA; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. Wayne_.; Harvard Medical School, Boston, MA, 02215, USA. Wayne_.
Pokaż więcej
Źródło:
Molecular cancer [Mol Cancer] 2024 Jan 09; Vol. 23 (1), pp. 8. Date of Electronic Publication: 2024 Jan 09.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
MeSH Terms:
Carcinoma, Renal Cell*/therapy
Kidney Neoplasms*/therapy
Humans ; Immunotherapy ; Cell- and Tissue-Based Therapy ; Combined Modality Therapy
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Hormone, Targeted, and Combinational Therapies for Breast Cancers: From Humans to Dogs.
Autorzy:
Ke CH; Sustainable Swine Research Center, National Pingtung University of Science and Technology, Pingtung 91201, Taiwan.; Animal Disease Diagnostic Center, College of Veterinary Medicine, National Pingtung University of Science and Technology, Pingtung 91201, Taiwan.
Lin CN; Sustainable Swine Research Center, National Pingtung University of Science and Technology, Pingtung 91201, Taiwan.; Animal Disease Diagnostic Center, College of Veterinary Medicine, National Pingtung University of Science and Technology, Pingtung 91201, Taiwan.; Department of Veterinary Medicine, College of Veterinary Medicine, National Pingtung University of Science and Technology, Pingtung 91201, Taiwan.
Lin CS; Department of Veterinary Medicine, School of Veterinary Medicine, National Taiwan University, Taipei 10617, Taiwan.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jan 05; Vol. 25 (2). Date of Electronic Publication: 2024 Jan 05.
Typ publikacji:
Systematic Review; Journal Article; Review
MeSH Terms:
Breast Neoplasms*/drug therapy
Humans ; Dogs ; Female ; Animals ; Prospective Studies ; Combined Modality Therapy ; Antibodies, Monoclonal/therapeutic use ; Hormones
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
p21 as a Predictor and Prognostic Indicator of Clinical Outcome in Rectal Cancer Patients.
Autorzy:
Ooi LC; Department of Anatomical Pathology, Liverpool Hospital, Liverpool, NSW 2170, Australia.
Ho V; School of Medicine, Western Sydney University, Penrith, NSW 2751, Australia.; Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia.
Zhu JZ; Department of Anatomical Pathology, Liverpool Hospital, Liverpool, NSW 2170, Australia.
Lim S; Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia.; Macarthur Cancer Therapy Centre, Campbelltown Hospital, Campbelltown, NSW 2560, Australia.; Discipline of Medical Oncology, School of Medicine, Western Sydney University, Liverpool, NSW 2170, Australia.
Chung L; School of Medicine, Western Sydney University, Penrith, NSW 2751, Australia.; Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia.
Abubakar A; School of Medicine, Western Sydney University, Penrith, NSW 2751, Australia.; Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia.
Rutland T; Department of Anatomical Pathology, Liverpool Hospital, Liverpool, NSW 2170, Australia.; School of Medicine, Western Sydney University, Penrith, NSW 2751, Australia.; Discipline of Pathology, School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia.
Chua W; School of Medicine, Western Sydney University, Penrith, NSW 2751, Australia.; Discipline of Medical Oncology, School of Medicine, Western Sydney University, Liverpool, NSW 2170, Australia.; Department of Medical Oncology, Liverpool Hospital, Liverpool, NSW 2170, Australia.
Ng W; Department of Medical Oncology, Liverpool Hospital, Liverpool, NSW 2170, Australia.
Lee M; Department of Radiation Oncology, Liverpool Hospital, Liverpool, NSW 2170, Australia.
Morgan M; Department of Colorectal Surgery, Liverpool Hospital, Liverpool, NSW 2170, Australia.
MacKenzie S; School of Medicine, Western Sydney University, Penrith, NSW 2751, Australia.; Department of Colorectal Surgery, Liverpool Hospital, Liverpool, NSW 2170, Australia.
Lee CS; Department of Anatomical Pathology, Liverpool Hospital, Liverpool, NSW 2170, Australia.; School of Medicine, Western Sydney University, Penrith, NSW 2751, Australia.; Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia.; Discipline of Pathology, School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jan 05; Vol. 25 (2). Date of Electronic Publication: 2024 Jan 05.
Typ publikacji:
Journal Article
MeSH Terms:
Rectal Neoplasms*/diagnosis
Rectal Neoplasms*/therapy
Humans ; Prognosis ; Combined Modality Therapy ; Adjuvants, Immunologic ; Adjuvants, Pharmaceutic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo.
Autorzy:
Brown EJ; Nuffield Department of Medicine, Centre for Medicines Discovery, University of Oxford, Oxford, UK.
Balaguer-Lluna L; SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Institut de Recerca Sant Joan de Deu, Barcelona, Spain.
Cribbs AP; Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, National Institute of Health Research Oxford Biomedical Research Unit (BRU), University of Oxford, Oxford, UK.; Oxford Centre for Translational Myeloma Research, University of Oxford, Oxford, UK.
Philpott M; Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, National Institute of Health Research Oxford Biomedical Research Unit (BRU), University of Oxford, Oxford, UK.; Oxford Centre for Translational Myeloma Research, University of Oxford, Oxford, UK.
Campo L; Department of Oncology, Experimental Cancer Medicine Centre, University of Oxford, Oxford, UK.
Browne M; Department of Oncology, Experimental Cancer Medicine Centre, University of Oxford, Oxford, UK.
Wong JF; Nuffield Department of Medicine, Centre for Medicines Discovery, University of Oxford, Oxford, UK.
Oppermann U; Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, National Institute of Health Research Oxford Biomedical Research Unit (BRU), University of Oxford, Oxford, UK.; Oxford Centre for Translational Myeloma Research, University of Oxford, Oxford, UK.
Carcaboso ÁM; SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Institut de Recerca Sant Joan de Deu, Barcelona, Spain.
Bullock AN; Nuffield Department of Medicine, Centre for Medicines Discovery, University of Oxford, Oxford, UK. .
Farnie G; Nuffield Department of Medicine, Centre for Medicines Discovery, University of Oxford, Oxford, UK. .; Oxford Centre for Translational Myeloma Research, University of Oxford, Oxford, UK. .; Cancer Research Horizons, The Francis Crick Institute, London, UK. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Jan 03; Vol. 14 (1), pp. 328. Date of Electronic Publication: 2024 Jan 03.
Typ publikacji:
Journal Article
MeSH Terms:
Brain Stem Neoplasms*/drug therapy
Brain Stem Neoplasms*/genetics
Glioma*/drug therapy
Glioma*/genetics
Brain Neoplasms*/drug therapy
Brain Neoplasms*/genetics
Child ; Humans ; Blood-Brain Barrier ; Cell Survival ; Combined Modality Therapy ; Mutation ; Protein-Arginine N-Methyltransferases/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The efficacy and safety of microneedling with topical tranexamic acid for melasma treatment: A systematic review and meta-analysis.
Autorzy:
Feng X; Department of Dermatovenerology, Chengdu First People's Hospital, Chengdu, China.
Su H; Department of Dermatovenerology, Chengdu First People's Hospital, Chengdu, China.
Xie J; Department of Orthopedics surgery, West China Hospital of Sichuan University, Chengdu, China.
Pokaż więcej
Źródło:
Journal of cosmetic dermatology [J Cosmet Dermatol] 2024 Jan; Vol. 23 (1), pp. 33-43. Date of Electronic Publication: 2023 Aug 16.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article; Review
MeSH Terms:
Tranexamic Acid*
Melanosis*/therapy
Melanosis*/drug therapy
Humans ; Percutaneous Collagen Induction ; Prospective Studies ; Combined Modality Therapy ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Pancreatic Cancer: A Review of Current Treatment and Novel Therapies.
Autorzy:
Kolbeinsson HM; Spectrum Health General Surgery Residency, Grand Rapids, Michigan, USA.; Department of Surgery, Michigan State University College of Human Medicine, Grand Rapids, Michigan, USA.
Chandana S; Department of Surgery, Michigan State University College of Human Medicine, Grand Rapids, Michigan, USA.; Cancer and Hematology Centers of Western Michigan, PC, Grand Rapids, Michigan, USA.
Wright GP; Spectrum Health General Surgery Residency, Grand Rapids, Michigan, USA.; Department of Surgery, Michigan State University College of Human Medicine, Grand Rapids, Michigan, USA.; Division of Surgical Oncology, Spectrum Health Medical Group, Grand Rapids, Michigan, USA.
Chung M; Spectrum Health General Surgery Residency, Grand Rapids, Michigan, USA.; Department of Surgery, Michigan State University College of Human Medicine, Grand Rapids, Michigan, USA.; Division of Surgical Oncology, Spectrum Health Medical Group, Grand Rapids, Michigan, USA.
Pokaż więcej
Źródło:
Journal of investigative surgery : the official journal of the Academy of Surgical Research [J Invest Surg] 2023 Dec 31; Vol. 36 (1), pp. 2129884. Date of Electronic Publication: 2022 Oct 03.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Pancreatic Neoplasms*/therapy
Pancreatic Neoplasms*/drug therapy
Antineoplastic Agents*/therapeutic use
Humans ; United States ; Combined Modality Therapy ; Neoadjuvant Therapy ; Pancreatic Neoplasms
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Consideration of SHP-1 as a Molecular Target for Tumor Therapy.
Autorzy:
Lim S; Division of Applied Life Science (BK21 Plus), Gyeongsang National University, Jinju 52828, Republic of Korea.
Lee KW; Anti-Aging Bio Cell Factory-Regional Leading Research Center, Gyeongsang National University, Jinju 52828, Republic of Korea.
Kim JY; Department of Pharmaceutical Engineering, Institute of Agricultural and Life Science (IALS), Gyeongsang National University, Jinju 52725, Republic of Korea.
Kim KD; Division of Applied Life Science (BK21 Plus), Gyeongsang National University, Jinju 52828, Republic of Korea.; Anti-Aging Bio Cell Factory-Regional Leading Research Center, Gyeongsang National University, Jinju 52828, Republic of Korea.; Plant Molecular Biology and Biotechnology Research Center (PMBBRC), Gyeongsang National University, Jinju 52828, Republic of Korea.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Dec 26; Vol. 25 (1). Date of Electronic Publication: 2023 Dec 26.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Epigenesis, Genetic*
Carcinogenesis*
Humans ; Combined Modality Therapy ; Catalytic Domain ; Janus Kinases ; Tumor Microenvironment
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The Biological and Clinical Role of the Telomerase Reverse Transcriptase Gene in Glioblastoma: A Potential Therapeutic Target?
Autorzy:
Di Nunno V; Nervous System Medical Oncology Department, IRCCS Istituto delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy.
Aprile M; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 40138 Bologna, Italy.
Bartolini S; Nervous System Medical Oncology Department, IRCCS Istituto delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy.
Gatto L; Department of Oncology, Azienda Unità Sanitaria Locale (AUSL) Bologna, 40139 Bologna, Italy.
Tosoni A; Nervous System Medical Oncology Department, IRCCS Istituto delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy.
Ranieri L; Nervous System Medical Oncology Department, IRCCS Istituto delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy.
De Biase D; Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.; Department of Pharmacy and Biotechnology (FaBit), University of Bologna, 40126 Bologna, Italy.
Asioli S; IRCCS Istituto delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy.; Department of Biomedical and Neuromotor Sciences (DIBINEM), Surgical Pathology Section, Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy.
Franceschi E; Nervous System Medical Oncology Department, IRCCS Istituto delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy.
Pokaż więcej
Źródło:
Cells [Cells] 2023 Dec 25; Vol. 13 (1). Date of Electronic Publication: 2023 Dec 25.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Glioblastoma*/drug therapy
Glioblastoma*/genetics
Telomerase*/genetics
Humans ; Central Nervous System ; Combined Modality Therapy ; Aggression
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Recombinant human adenovirus p53 combined with transcatheter arterial chemoembolization for liver cancer: A meta-analysis.
Autorzy:
Guo Y; Department of Radiation, Xuzhou first People's Hospital, Jiangsu, China.
Chen Y; Department of Radiation, Xuzhou first People's Hospital, Jiangsu, China.
Zhang Y; Department of Radiation, Xuzhou first People's Hospital, Jiangsu, China.
Xu M; Department of Radiation, Xuzhou first People's Hospital, Jiangsu, China.
Guo W; Department of Radiation, Xuzhou first People's Hospital, Jiangsu, China.
Zhang J; Department of Radiation, Xuzhou first People's Hospital, Jiangsu, China.
Ma G; Department of Radiation, Xuzhou first People's Hospital, Jiangsu, China.
Liu C; Xuzhou Medical University, Jiangsu, China.
Yang J; Xuzhou Medical University, Jiangsu, China.
Wu X; Department of Radiation, Xuzhou first People's Hospital, Jiangsu, China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Dec 21; Vol. 18 (12), pp. e0295323. Date of Electronic Publication: 2023 Dec 21 (Print Publication: 2023).
Typ publikacji:
Meta-Analysis; Journal Article
MeSH Terms:
Liver Neoplasms*/pathology
Carcinoma, Hepatocellular*/pathology
Adenoviruses, Human*/genetics
Chemoembolization, Therapeutic*/methods
Humans ; Tumor Suppressor Protein p53/genetics ; Quality of Life ; Combined Modality Therapy ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effect of Vagus Nerve Stimulation on the GASH/Sal Audiogenic-Seizure-Prone Hamster.
Autorzy:
Gonçalves-Sánchez J; Department of Cellular Biology and Pathology, School of Medicine, University of Salamanca, 37007 Salamanca, Spain.; Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.; Institute of Neuroscience of Castilla y León, 37007 Salamanca, Spain.
Sancho C; Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.; Institute of Neuroscience of Castilla y León, 37007 Salamanca, Spain.; Department of Physiology and Pharmacology, School of Medicine, University of Salamanca, 37007 Salamanca, Spain.
López DE; Department of Cellular Biology and Pathology, School of Medicine, University of Salamanca, 37007 Salamanca, Spain.; Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.; Institute of Neuroscience of Castilla y León, 37007 Salamanca, Spain.
Castellano O; Department of Cellular Biology and Pathology, School of Medicine, University of Salamanca, 37007 Salamanca, Spain.; Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.; Institute of Neuroscience of Castilla y León, 37007 Salamanca, Spain.
García-Cenador B; Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.; Department of Surgery, School of Medicine, University of Salamanca, 37007 Salamanca, Spain.
Servilha-Menezes G; Department of Physiology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14040-900, SP, Brazil.
Corchado JM; Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.; Bioinformatics, Intelligent Systems and Educational Technology (BISITE) Research Group, 37007 Salamanca, Spain.
García-Cairasco N; Department of Physiology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14040-900, SP, Brazil.
Gonçalves-Estella JM; Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.; Department of Surgery, School of Medicine, University of Salamanca, 37007 Salamanca, Spain.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Dec 20; Vol. 25 (1). Date of Electronic Publication: 2023 Dec 20.
Typ publikacji:
Journal Article
MeSH Terms:
Vagus Nerve Stimulation*
Epilepsy, Reflex*
Animals ; Cricetinae ; Seizures/therapy ; Brain ; Combined Modality Therapy ; Interleukin-1beta
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Role of Single-Nucleotide Polymorphisms in Genes Implicated in Capecitabine Pharmacodynamics on the Effectiveness of Adjuvant Therapy in Colorectal Cancer.
Autorzy:
Cura Y; Pharmacy Service, Pharmacogenetics Unit, University Hospital Virgen de las Nieves, 18014 Granada, Spain.
Sánchez-Martín A; Pharmacy Service, Pharmacogenetics Unit, University Hospital Virgen de las Nieves, 18014 Granada, Spain.
Márquez-Pete N; Pharmacy Service, Pharmacogenetics Unit, University Hospital Virgen de las Nieves, 18014 Granada, Spain.
González-Flores E; Medical Oncology, University Hospital Virgen de las Nieves, 18014 Granada, Spain.; Biomedical Research Institute-ibs.Granada, 18012 Granada, Spain.
Martínez-Martínez F; Pharmaceutical Care Research Group, Pharmacy Faculty, University of Granada, 18016 Granada, Spain.
Pérez-Ramírez C; Department of Biochemistry and Molecular Biology II, Institute of Nutrition and Food Technology 'José Mataix', Center of Biomedical Research, University of Granada, 18016 Granada, Spain.
Jiménez-Morales A; Pharmacy Service, Pharmacogenetics Unit, University Hospital Virgen de las Nieves, 18014 Granada, Spain.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Dec 20; Vol. 25 (1). Date of Electronic Publication: 2023 Dec 20.
Typ publikacji:
Journal Article
MeSH Terms:
Polymorphism, Single Nucleotide*
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/genetics
Humans ; Capecitabine/pharmacology ; Capecitabine/therapeutic use ; Combined Modality Therapy ; Alleles ; Adjuvants, Immunologic ; Adjuvants, Pharmaceutic ; X-ray Repair Cross Complementing Protein 1
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Targeting Farnesoid X Receptor in Tumor and the Tumor Microenvironment: Implication for Therapy.
Autorzy:
Nenkov M; Section Pathology of the Institute of Forensic Medicine, Jena University Hospital, Friedrich Schiller University Jena, Am Klinikum 1, 07747 Jena, Germany.
Shi Y; California Pacific Medical Center Research Institute, Sutter Bay Hospitals, San Francisco, CA 94107, USA.
Ma Y; Section Pathology of the Institute of Forensic Medicine, Jena University Hospital, Friedrich Schiller University Jena, Am Klinikum 1, 07747 Jena, Germany.
Gaßler N; Section Pathology of the Institute of Forensic Medicine, Jena University Hospital, Friedrich Schiller University Jena, Am Klinikum 1, 07747 Jena, Germany.
Chen Y; Section Pathology of the Institute of Forensic Medicine, Jena University Hospital, Friedrich Schiller University Jena, Am Klinikum 1, 07747 Jena, Germany.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Dec 19; Vol. 25 (1). Date of Electronic Publication: 2023 Dec 19.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Neoplasms*/drug therapy
Humans ; Combined Modality Therapy ; Bile Acids and Salts ; Homeostasis ; Immune Checkpoint Inhibitors ; Tumor Microenvironment ; Receptor, Muscarinic M3
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 41-60 z 37344

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies